ST Segment Yükselmeli Miyokard İnfarktüsü Hastalarında Koroner Arter Hastalığının Ciddiyeti ile Serum Adropin Seviyesi Arasındaki İlişkinin Değerlendirilmesi

Abstract

Amaç: Adropin doku ve organların enerji balansı ile ilişkilidir. SYNTAX skor (SS) ST segment yükselmeli miyokard infraktüsünün (STYMI) ciddiyetinin değerlendirilmesinde kullanılmaktadır. Bu çalışmada serum adropinseviyesiile STYMI hastalarının hastalık ciddiyeti arasındaki ilişkinin araştırılması amaçlandı. GereçveYöntemler: STYMI sebebiyle koroner anjiografi (KAG) yapılan 89 hasta çalışmaya dahil edildi. STYMI hastalar Grup 1 (SS < 22) ve Grup 2 (SS ≥ 23) alt gruplarına ayrıldı. KAG yapılan ve normal koroner arterler izlenen 43 hasta ise control grubu olarak çalışmaya dahil edildi. Bulgular: Grup 1 ve 2 de erkek cinsiyet control grubuna gore daha fazlaydı (sırasıyla % 89,7, 74,2 ve 34,9, p < 0.001). Sigara kullanım oranı Grup 1 ve 2 de kontrol grubuna gore daha fazlaydı (sırasıyla %55,1, 34,4ve 11,6, p≤0.001). Serum adropin seviyesi Grup 1 de kontrol grubuna göre anlamlı daha azdı (147,3 ± 149,2 mg/L ile 228,1 ± 253,3 ng/L, p = 0.03). Serum adropin seviyesi en düşük Grup 2 de saptandı (87,8 ± 23,2 ng/L, 147,3 ± 149,2 ng/L ve 228,1 ± 253,3 ng/L, p = 0.004). Serum adropin seviyesi SS ile negatif koroleydi (r = -0.33, p = 0.002). Sonuç: STYMI hastalarında serum adropin seviyeleri koroner arter hastalığı (KAH) olmayanlara göre düşüktür. SS yükseldikçe serum adropin seviyeleri azalmaktadır, bu da KAH ciddiyetini göstermektedir.

Keywords

• Adropin
• ST-segment yükselmeli miyokardial enfarktüs
• SYNTAX skor

An Analysis on Coronary Artery Disease Severity with Serum Adropin Level in Patients with Acute ST-Segment Elevation Myocardial Infarction

Abstract

Objective: Adropin is associated with energy balance in tissues and organs. The SYNTAX score (SS) is used to determine the severity of ST-segment elevation myocardial infarction (STEMI). The aim of this study was to determine the relationship between serum adropin levels and disease severity in STEMI patients. Materials and Methods: Eighty-nine patients who underwent coronary angiography (CAG) for STEMI were included in the study. The STEMI patients were divided into two subgroups: Group 1(SS < 22) and Group 2 (SS ≥ 23). 43 patients who underwent CAG and had normal coronary arteries were included in the study as a control group. Results: Groups 1 and 2 included more male participants than the control group (89.7% and 74.2% vs. 34.9%, respectively, p < 0.001). The smoking rate was higher in Groups 1 and 2 than in the control group (55.1% and 34.4% vs. 11.6%, respectively, p≤0.001). Serum adropin levels were lower in Group 1 than in the control group (147.3 ± 149.2 mg/L and 228.1 ± 253.3 ng/L, p = 0.03). Serum adropin levels were the lowest in Group 2 (87.8 ± 23.2 ng/L, 147.3 ± 149.2 ng/L, and 228.1 ± 253.3 ng/L, p = 0.004). Serum adropin levels were also negatively correlated with SS (r = -0.33, p = 0.002). Conclusion: Serum adropin levels decreased more in STEMI patients than in those without coronary artery disease (CAD). In addition, serum adropin levels decreased with increasing SS;this indicates the severity of CAD.

Keywords

• Adropin
• ST-segment elevation myocardial infarction
• SYNTAX score

References

1. 1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). European heart journal 2019; 40(3): 237-69.
2. 2. Hassan AK, Bergheanu SC, Hasan-Ali H, et al. Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention. The American journal of cardiology 2009; 103(6): 779-84.
3. 3. Danese E and Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med 2016; 4(10): 194. doi: 10.21037/atm.2016.05.19.
4. 4. Mythili S and Malathi N. Diagnostic markers of acute myocardial infarction. Biomed Rep 2015; 3(6): 743-8.
5. 5. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008; 8: 468-81.
6. 6. Yosaee S, Soltani S, Sekhavati E, et al. Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article. Iran J Public Health 2016; 45: 1568-76.
7. 7. Yu HY, Zhao P, Wu MC, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 2014; 191: 46-49.
8. 8. Lian W, Gu X, Qin Y, et al. Elevated plasma levels of adropin in heart failure patients. Intern Med 2011; 50(15): 1523-7.

9. 9. Zhao LP, Xu WT, Wang L, et al. Serum adropin level in patients with stable coronary artery disease. Heart, lung & circulation 2015; 24(10): 975-9.
10. 10. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1(2): 219-27.
11. 11. Farooq V, Serruys PW, Bourantas CV, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013; 128(2): 141-51.
12. 12. Brown AJ, McCormick LM, Gajendragadkar PR, et al. Initial SYNTAX score predicts major adverse cardiac events after primary percutaneous coronary intervention. Angiology 2014; 65(5): 408-12.
13. 13. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013; 380: 73-81.
14. 14. Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012; 20(7): 1394-402.
15. 15. Diez-Delhoyo F, Gutierrez-Ibanes E, Sanz-Ruiz R, et al. Prevalence of Microvascular and Endothelial Dysfunction in the Nonculprit Territory in Patients With Acute Myocardial Infarction. Circ Cardiovasc Interv 2019; 12(2): doi: 10.1161/ circinterventions.118.007257.
16. 16. Qiu CR, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance. Angiology 2017; 68: 354-9.
17. 17. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010; 122: 185-92.
18. 18. Chen X, Xue H, Fang W, et al. Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. Redox Biol 2019; 21: 101068. 2019/01/27. doi: 10.1016/j.redox.2018.101068.
19. 19. Zhao LP, You T, Chan SP, et al. Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exp Ther Med 2016; 11: 1065-70.
20. 20. Ertem AG, Unal S, Efe TH, et al. Association between serum adropin level and burden of coronary artery disease in patients with non-ST elevation myocardial infarction. Anatol J Cardiol 2017; 17(2): 119-24.